Stock Track | Harrow Health Plummets 13.26% in Pre-Market on Disappointing Q1 Earnings and Revenue Miss

Stock Track05-12

Harrow Health Inc's stock plummeted 13.26% in pre-market trading on Tuesday.

The sharp decline was driven by the company's release of first-quarter 2026 financial results, which significantly missed analyst expectations. Harrow reported a loss of $0.74 per share, much worse than the consensus estimate of a $0.39 loss, while revenue of $44.2 million fell 15.68% short of the $52.4 million forecast. The company's net loss widened to $27.6 million, and gross margin contracted to 61% from 68% a year earlier.

Management attributed part of the revenue shortfall to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Despite the disappointing quarterly performance, the company reaffirmed its full-year 2026 revenue guidance and projected improved second-quarter revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment